
|Articles|May 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 5
- Volume 16
- Issue 5
AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
Advertisement
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
about 19 years ago
Escalating Drug Costs Could Provoke Consumer Backlashabout 19 years ago
Large Study Casts Doubt on Value of CADabout 19 years ago
Cetuximab Does Not Increase Mucositis in H&N Cancerabout 19 years ago
2004 Update Shows Continued Lower Breast Ca Incidenceabout 19 years ago
Reclast Single-Dose Infusion Approved for Paget's Diseaseabout 19 years ago
Fragmin Approved for VTE in Cancer Ptsabout 19 years ago
New Phase III Trial of Genasense in Advanced Melanoma Plannedabout 19 years ago
Cervical Cancer Vaccines Show Sustained Protectionabout 19 years ago
The 'New' Medicare: Passive Payer No More; PQRI Is First StepAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
2
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
3
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
4
Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC
5













































































